Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics, Inc. TN-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (RAHC) caused by mutations in the PKP2 gene Orphan Drug Designation for TN-401 is the first for a gene therapy treatment for ARVCs Expect to Submit TN-401 IND Application to FDA in 2023 SOUTH SAN FRANCISCO, Calif., Nov. 28, …